ProBioGen AG

Silver Sponsor

ProBioGen is a premiere, Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, together with intelligent product-specific technologies yields biologics with optimized properties.

ProBioGen has been operational for 30 years. At four locations in Berlin, about 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

STATE-OF-THE-ART DEVELOPMENT PLATFORMS:

• Royalty-free, fee-for-service-based
• Proprietary CHO.RiGHT® expression platform, based on different CHO host cell lines,
• own expression vectors and a chemically defined media platform
• Novel proprietary DirectedLuck transposase expression technology could increase titers of clones up to 8 g/L (standard titer 3-5 g/L)
• Achieving high monoclonality rates in only one round of Single Cell Cloning 
• Stable cell line development, from lead optimization up to the generation of biopharmaceutical producer cell lines (antibodies, bi- and multi-specific molecules, Fc fusions, recombinant proteins, cytokines, enzymes, clotting factors, fusion proteins, etc.)
• Robust and economical process development (up- and downstream) 
• Predictive Bioprocess Scale-Down Models in Place
• Rapid and reliable non-GMP and GMP manufacturing (250L & 1000 L disposable bioreactors)
• Full analytical methods development and validation
• Sophisticated cell-based activity assays

INNOVATIVE PLATFORM TECHNOLOGIES:

• GlymaxX® ADCC Enhancement Technology to boost the cell-killing potency of antibodies against cancerous or infected cells by preventing fucose biosynthesis. Permanent cell line modification: applicable also to any existing antibody-producing cell line and entire expression platforms
• Novel proprietary DirectedLuck® transposase for efficient gene delivery, homogenous clone pools & high-titer clones (up to 8 g/L). Cuts hands-on lab time and overall time lines
• Galactosylation adjustment: permanent cell line modification, applicable to any existing antibody cell lines and entire expression platforms
• Sialylation adjustment: permanent cell line modification, applicable to any existing protein producer cell lines and entire expression platforms
• Lenti.RiGHT® packaging and producer cell line: Our lentivirus production platform is based on HEK293 packaging cells stably transfected with all necessary viral components. It enables an inducible, scalable and efficient production of high-titer lentiviral particles for gene transfer applications.
• Avian AGE1.CR® designer producer cell lines to replace conventional use of primary chicken cells. AGE1.CR® cell lines grow in suspension, reaching viral titers of up to 10E09 PFU/ml. Established USP/DSP for industrial viral vaccine manufacturing with superior properties for rapid, fully scalable and safe production in place
• Human neuronal AGE1.HN® cell line to express complex, highly branched and sialylated human glycoproteins or viral vaccines

website